Vita 34 AG announces preliminary, unaudited results for the fiscal year 2013

(PresseBox) ( Leipzig, )
Vita 34 AG (WKN A0BL84), the largest private stem cell bank in the Germanspeaking countries, announces preliminary, unaudited results according to the International Reporting Standards (IFRS) for the fiscal year 2013. For the fiscal year 2013 Vita 34 AG expects to generate revenue on about the same level of the previous year with 13.6 million Euro (2012: 13.6 million Euro) and earnings before interest, taxes, depreciation and amortization (EBITDA) of approximately 2.7 million Euro (2012: 0.4 million Euro) and thus exceeds the estimation published on 24 October 2013.
The publisher indicated in each case is solely responsible for the press releases above, the event or job offer displayed, and the image and sound material used (see company info when clicking on image/message title or company info right column). As a rule, the publisher is also the author of the press releases and the attached image, sound and information material.
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to